title: Versatile immunomagnetic nanocarrier platform for capturing cancer cells.
abstract: Sensitive and quantitative assessment of changes in circulating tumor cells (CTCs) can help in cancer prognosis and in the evaluation of therapeutics efficacy. However, extremely low occurrence of CTCs in the peripheral blood (approximately one CTC per billion blood cells) and potential changes in molecular biomarkers during the process of epithelial to mesenchymal transition create technical hurdles to the enrichment and enumeration of CTCs. Recently, efforts have been directed toward development of antibody-capture assays based on the expression of the common biomarker-the epithelial cell adhesion molecule (EpCAM) of epithelium-derived cancer cells. Despite some promising results, the assays relying on EpCAM capture have shown inconsistent sensitivity in clinical settings and often fail to detect CTCs in patients with metastatic cancer. We have addressed this problem by the development of an assay based on hybrid magnetic/plasmonic nanocarriers and a microfluidic channel. In this assay, cancer cells are specifically targeted by antibody-conjugated magnetic nanocarriers and are separated from normal blood cells by a magnetic force in a microfluidic chamber. Subsequently, immunofluorescence staining is used to differentiate CTCs from normal blood cells. We demonstrated in cell models of colon, breast, and skin cancers that this platform can be easily adapted to a variety of biomarkers, targeting both surface receptor molecules and intracellular biomarkers of epithelial-derived cancer cells. Experiments in whole blood showed capture efficiency greater than 90% when two cancer biomarkers are used for cell capture. Thus, the combination of immunotargeted magnetic nanocarriers with microfluidics provides an important platform that can improve the effectiveness of current CTC assays by overcoming the problem of heterogeneity of tumor cells in the circulation.
authors.affiliation: Department of Biomedical Engineering, University of Texas at Austin , Austin, Texas 78712, United States.
authors.forename: Chun-Hsien
authors.initials: CH
authors.lastname: Wu
authors.forename: Yu-Yen
authors.initials: YY
authors.lastname: Huang
authors.forename: Peng
authors.initials: P
authors.lastname: Chen
authors.forename: Kazunori
authors.initials: K
authors.lastname: Hoshino
authors.forename: Huaying
authors.initials: H
authors.lastname: Liu
authors.forename: Eugene P
authors.initials: EP
authors.lastname: Frenkel
authors.forename: John X J
authors.initials: JX
authors.lastname: Zhang
authors.forename: Konstantin V
authors.initials: KV
authors.lastname: Sokolov
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D006801:Humans; D018189:Immunomagnetic Separation; D046529:Microscopy, Electron, Transmission; D049329:Nanostructures; D009369:Neoplasms / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor
references.citation: ACS Nano. 2012 May 22;6(5):4483-93
references.pmid: 22540892
references.citation: Cancer Treat Rev. 2011 Dec;37(8):579-89
references.pmid: 21592671
references.citation: J Clin Oncol. 2005 Mar 1;23(7):1420-30
references.pmid: 15735118
references.citation: J Biomed Opt. 2007 May-Jun;12(3):034007
references.pmid: 17614715
references.citation: J Natl Cancer Inst. 2009 Jan 7;101(1):61-6
references.pmid: 19116383
references.citation: Phys Chem Chem Phys. 2013 Mar 7;15(9):3022-6
references.pmid: 23138867
references.citation: ACS Nano. 2009 Jan 27;3(1):16-20
references.pmid: 19206243
references.citation: Ann Oncol. 2010 Sep;21(9):1851-1857
references.pmid: 20147742
references.citation: ACS Nano. 2011 Nov 22;5(11):8532-40
references.pmid: 21999459
references.citation: N Engl J Med. 2004 Aug 19;351(8):781-91
references.pmid: 15317891
references.citation: J Am Chem Soc. 2006 Jun 7;128(22):7383-9
references.pmid: 16734494
references.citation: Nano Lett. 2009 Oct;9(10):3612-8
references.pmid: 19645464
references.citation: Anal Chem. 2012 May 15;84(10):4292-9
references.pmid: 22510236
references.citation: Gastroenterology. 2010 Mar;138(3):949-57.e1-7
references.pmid: 19931263
references.citation: Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5
references.pmid: 17079488
references.citation: Nature. 2007 Dec 20;450(7173):1235-9
references.pmid: 18097410
references.citation: Nat Mater. 2008 Jun;7(6):442-53
references.pmid: 18497851
references.citation: Clin Cancer Res. 2007 Feb 1;13(3):920-8
references.pmid: 17289886
references.citation: Cancer Res. 2008 Feb 1;68(3):645-9
references.pmid: 18245462
references.citation: Adv Carbohydr Chem. 1956;48(11):1-41
references.pmid: 13469627
references.citation: J Am Chem Soc. 2009 Jul 22;131(28):9728-34
references.pmid: 19435348
references.citation: ACS Nano. 2010 Sep 28;4(9):5163-73
references.pmid: 20690598
references.citation: Breast Cancer Res Treat. 2004 Sep;87(1):87-95
references.pmid: 15377854
references.citation: Breast Cancer Res Treat. 2011 May;127(1):33-41
references.pmid: 20379845
references.citation: Breast Cancer Res. 2009;11(4):R46
references.pmid: 19589136
references.citation: J Phys Chem B. 2005 Nov 24;109(46):21593-601
references.pmid: 16853803
references.citation: Nat Protoc. 2008;3(2):314-20
references.pmid: 18274533
references.citation: Nano Lett. 2012 Jun 13;12(6):3231-7
references.pmid: 22587495
references.citation: PLoS One. 2010 Sep 08;5(9):e12517
references.pmid: 20838621
references.citation: ACS Nano. 2011 Aug 23;5(8):6619-28
references.pmid: 21761914
references.citation: Lab Chip. 2011 Oct 21;11(20):3449-57
references.pmid: 21863182
references.citation: Nano Lett. 2007 May;7(5):1338-43
references.pmid: 17439187